Abstract

The Clinical &Translational Research Center (CTRC), established in 1990 and rated Outstanding in the 2008 CCSG review, focuses on new drug development. This comprehensive 18-bed combined treatment and laboratory unit serves as the primary site for personalized, protocol-based, innovative clinical and translational research. Services provided are research infrastructure and oversight as well as 24-hour phlebotomy/lab support for pharmacologic testing. Other services include specialized processing for DNA and RNA analysis, real-time internet-based tracking of audit time-points, Ei

Public Health Relevance

The CTRC is the primary site of new drug studies for cancer and related diseases, and since 2007 it has activated 274 protocols - including many first-in-man studies. Seventeen (17) drugs approved by the FDA since 2007 were studied in Phase I or II trials in the CTRC. NIH Cooperative Group and NCI protocols represented 11% of studies activated during the grant period and MD Anderson investigator initiated studies comprised 5%. Of the total 4,057 protocol registrations, NIH peer-reviewed studies accounted for 531 (13%).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759805
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$296,418
Indirect Cost
$111,234

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141

Showing the most recent 10 out of 12418 publications